Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Rabies virus glycoprotein and immune response pattern using recombinant protein or recombinant RNA viral vectors

Full text
Author(s):
Astray, Renato M. [1] ; Ventini, Daniella C. [1] ; Boldorini, Vera L. L. [1] ; Silva, Fernanda G. [1] ; Rocca, Mayra P. [1] ; Pereira, Carlos A. [1]
Total Authors: 6
Affiliation:
[1] Inst Butantan, Lab Imunol Viral, BR-05503900 Sao Paulo - Brazil
Total Affiliations: 1
Document type: Journal article
Source: Vaccine; v. 32, n. 24, SI, p. 2829-2832, MAY 19 2014.
Web of Science Citations: 6
Abstract

The present study shows the humoral and cellular aspects of immune response generated by a recombinant rabies virus glycoprotein (rRVGP) as compared to those generated by viral vector carrying the RNA coding for this protein (RVGP-RNA). The rRVGP was synthesized by stably transfected Drosophila melanogaster Schneider 2 (S2) cells and the RVGP-RNA was carried by a recombinant Semiliki Forest Virus (SFV-RVGP). The data show that protein as well as the RNA vaccine was capable of inducing reasonably acceptable levels of antibodies as compared to the optimized commercial whole virus vaccine. As expected, the RNA vaccine was clearly more effective than the protein vaccines in inducing a cellular immune response, as evaluated by the IgG2a/IgG1 ratio and synthesis of interferon gamma (IFN gamma) and interleukin 2 (IL2). Our study supports the importance of vaccine designing taking into consideration the concept of DNA/RNA ability to induce an effective cell immune response. (C) 2014 Elsevier Ltd. All rights reserved. (AU)

FAPESP's process: 09/09327-7 - Development of a bioprocess with S2 cells for production and purification of the recombinant rabies virus glycoprotein and study of its antigenicity
Grantee:Carlos Augusto Pereira
Support type: Regular Research Grants